Which hydroxy? Evidence for species differences in the regioselectivity of glucuronidation in rat, dog, and human in vitro systems and dog in vivo

Drug Metabolism and Disposition

Volumn 34, Issue 9, 2006, Pages 1502-1507

  Martin, Iain J ^a,b   Lewis, Richard J ^a   Bernstein, Michael A ^a   Beattie, Iain G ^a   Martin, Craig A ^a   Riley, Robert J ^a   Springthorpe, Brian ^a  

^a ASTRAZENECA   (United Kingdom)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (HYDROXYMETHYL) 5 [7 (2 PHENYLCYCLOPROPYL)AMINO] 5 (PROPYLTHIO) 3H [1,2,3]TRIAZOLO[4,5 D]PYRIMIDIN 3 YL]CYCLOPENTANE 1,2 DIOL; ACETYLACETONE; ANTICOAGULANT AGENT; AZ 11939714; DRUG METABOLITE; GLUCURONIDE; UNCLASSIFIED DRUG; URIDINE DIPHOSPHATE GLUCURONIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BILE COMPOSITION; CONTROLLED STUDY; GLUCURONIDATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; MALE; MASS SPECTROMETRY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; REGIONALIZATION; SPECIES DIFFERENCE;

ANIMALS; BILE; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COMPUTER SIMULATION; DOGS; DRUG EVALUATION, PRECLINICAL; FIBRINOLYTIC AGENTS; GLUCURONIDES; HEPATOCYTES; HUMANS; LIVER; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MASS SPECTROMETRY; MICROSOMES, LIVER; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; RATS; RATS, SPRAGUE-DAWLEY; REPRODUCIBILITY OF RESULTS; SPECIES SPECIFICITY;

CANIS FAMILIARIS;

EID: 33747856746     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.009282     Document Type: Article

References (24)

1. Bernstein MA and Lewis RJ (2004) New horizons for nuclear magnetic resonance. Eur Pharm Rev 9:57-63.
2. Boersma MG, van der Woude H, Bogaards J, Boeren S, Vervoort J, Cnubben NH, van Iersel ML, van Bladeren PJ, and Rietjens IM (2002) Regioselectivity of phase II metabolism of luteolin and quercetin by UDP-glucuronosyl transferases. Chem Res Toxicol 15:662-670.
3. Bouska JJ, Bell RL, Goodfellow CL, Stewart AO, Brooks CDW, and Carter GW (1997) Improving the in vivo duration of 5-lipoxygenase inhibitors: application of an in vitro glucuronosyltransferase assay. Drug Metab Dispos 25:1032-1038.
4. Burchell B and Coughtrie MWH (1989) UDP-Glucuronosyltransferases. Pharmacol Ther 43:261-289.
5. Burchell B, Nebert DW, Nelson DR, Bock KW, Iyanagi T, Jansen PL, Lancet D, Mulder GJ, Chowdhury JR, Siest G, et al. (1991) The UDP glucuronosyltransferase gene superfamily: suggested nomenclature based on evolutionary divergence. DNA Cell Biol 10:487-494.
6. Clarke DJ and Burchell B (1994) The uridine diphosphate glucuronosyl transferase multigene family - function and regulation. Handb Exp Pharmacol 112:3-43.
7. Court MH, Duan SX, von Moltke LL, Greenblatt DJ, Patten CJ, Miners JO, and MacKenzie PI (2001) Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms. J Pharmacol Exp Ther 299:998-1006.
8. Davis AM and Riley RJ (2004) Predictive ADMET studies, the challenges and the opportunities. Curr Opin Chem Biol 8:378-386.
9. Desmoulin F, Gilard V, Martino R, and Malet-Martino M (2003) Isolation of an unknown metabolite of capecitabine, an oral 5-fluorouracil prodrug, and its identification by nuclear magnetic resonance and liquid chromatography-tandem mass spectrometry as a glucuroconjugate of 5′-deoxy-5-fluorocytidine, namely 2′-(β-D-glucuronic acid)-5′-deoxy-5-fluorocytidine. J Chromatogr B 792:323-332.
10. Dutton GJ (1980) Glucuronidation of Drugs and Other Compounds. CRC Press, Boca Raton, FL.
11. Jin C-J, Mackenzie PI, and Miners JO (1997) The regio- and stereo-selectivity of C19 and C21 hydroxysteroid glucuronidation by UGT2B7 and UGT2B11. Arch Biochem Biophys 341:207-211.
12. Kaji H and Kume T (2005) Regioselective glucuronidation of denopamine: marked species differences and identification of human UDP- glucuronosyltransferase isoform. Drug Metab Dispos 33:403-412.
13. Lewis RJ, Bernstein MA, Duncan SJ, and Sleigh CJ (2005) A comparison of capillary-scale LC-NMR with alternative techniques: spectroscopic and practical considerations. Magn Reson Chem 43:783-789.
14. Lin JH and Wong BK (2002) Complexities of glucuronidation affecting in vitro-in vivo extrapolation. Curr Drug Metab 3:623-646.
15. McGinnity DF, Soars MG, Urbanowicz RA, and Riley RJ (2004) Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. Drug Metab Dispos. 32:1247-1253.
16. Miners JO and Mackenzie PI (1991) Drug glucuronidation in humans. Pharmacol Ther 51:347-369.
17. Ohkubo T, Takahashi A, and Nambara T (1990) Multiplicity of in vitro glucuronidation of 2-hydroxyestriol. J Steroid Biochem 36:501-503.
18. Pless D, Gouze JN, Senay C, Herber R, Leroy P, Barberousse V, Fournel-Gigleux S, and Magdalou J (1999) Characterization of the UDP-glucuronosyltransferases involved in the glucuronidation of an antithrombotic thioxyloside in rat and humans. Drug Metab Dispos 27:588-595.
19. Sandvoss M, Bardsley B, Beck TL, Lee-Smith E, North SE, Moore PJ, Edwards AJ, and Smith RJ (2005) HPLC-SPE-NMR in pharmaceutical development: capabilities and applications. Magn Reson Chem 43:762-770.
20. Sharer JE, Shipley LA, Vandenbranden MR, Binkley SN, and Wrighton SA (1995) Comparisons of phase I and phase II in vitro hepatic enzyme activities of human, dog, rhesus monkey, and cynomolgus monkey. Drug Metab Dispos 23:1231-1241.
21. Shimada K, Yumura Y, Terashima E, and Nambara T (1984) In vitro metabolic conjugation of catechol estrogens. J Steroid Biochem 20:1163-1167.
22. Smallcombe SH, Patt SL, and Keifer PA (1995) WET solvent suppression and its applications to LC NMR and high-resolution NMR spectroscopy. J Magn Reson (Ser A) 117:295-303.
23. Soars MG, Burchell B, and Riley RJ (2002) In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance. J Pharmacol Exp Ther 301:382-390.
24. Soars MG, Riley RJ, Findlay KAB, Coffey MJ, and Burchell B (2001) Evidence for significant differences in microsomal drug glucuronidation by canine and human liver and kidney. Drug Metab Dispos 29:121-126.